Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10158102" target="_blank" >RIV/00098892:_____/23:10158102 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216305:26220/22:PU145499 RIV/00216224:14110/23:00130052 RIV/61989592:15110/23:73613883 RIV/65269705:_____/23:00076398

Výsledek na webu

<a href="https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3264" target="_blank" >https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3264</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2022.039" target="_blank" >10.5507/bp.2022.039</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

Popis výsledku v původním jazyce

Aims. The study analysed post-acute COVID symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18–100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 – 25th December 2020. The initial examination was performed 4–12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.

Název v anglickém jazyce

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

Popis výsledku anglicky

Aims. The study analysed post-acute COVID symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18–100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 – 25th December 2020. The initial examination was performed 4–12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

<a href="/cs/project/VI04000039" target="_blank" >VI04000039: Systém včasného záchytu infekce COVID-19 pro bezpečnost ohrožených skupin obyvatelstva s využitím umělé inteligence</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Svazek periodika

167

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

185-191

Kód UT WoS článku

000863250600001

EID výsledku v databázi Scopus

2-s2.0-85151320249